Drugs / Latiglutenase
Latiglutenase
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT01917630 | Aug 2013 → Apr 2015 | celiac disease | Alvine Pharmaceuticals Inc. | Unknown | Missed primary |
| Phase 2 | NCT01255696 | Nov 2010 → May 2011 | celiac disease | Alvine Pharmaceuticals Inc. | Completed | Met primary |
| Phase 2 | NCT00959114 | Aug 2009 → Aug 2010 | celiac disease | Alvine Pharmaceuticals Inc. | Completed | Met primary |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT00669825 Comparator | Mar → Oct 2008 | celiac disease | Alvine Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00626184 Comparator | Feb → May 2008 | celiac disease | Alvine Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04839575 Comparator | Apr 2021 → Dec 2022 | celiac disease | Entero Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04243551 Comparator | Nov 2019 → Oct 2023 | celiac disease | Entero Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03585478 Comparator | Mar 2019 → Jan 2021 | celiac disease | Immunogenics, LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latiglutenase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585478 ↗ |
| Known as | ALV003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01255696 ↗ |
| Known as | Glutenase | “Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.” PMID 24583059 ↗ Feb 2014 |
| Modality | Protein / enzyme biologic | “ALV003 is an orally administered mixture of two recombinant proteases” NCT00959114 ↗ |
| Route | Other | “Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg” NCT00669825 ↗ |